- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03307941
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA (ARTEMIS-Eso)
Assessment of Metabolic and Pathological Response to Treatment With RCT and ImT Before Surgery in Locally Advanced Esophageal and Gastro-esophageal Junction Cancer: ARTemIS-Eso, a Three-level, Open-label, Phase I-II Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is indicated to patients with adenocarcinomas of the esophagus or gastro-esophageal junction and squamous cell carcinoma of the esophagus.
The study consists of 2 parts:
Phase I of the study is composed of the 3 following levels, corresponding to changes in the schedule and the number of administrations of monalizumab:
Level 1: monalizumab (ImT) administration starts 2 weeks after the end of RCT (Total of 3 ImT doses). A maximum of 7 days delay is allowed.
Level 2: monalizumab administration starts directly at the end of RCT (Total of 4 ImT doses). The first dose of monalizumab should be given on the following working day after the last radiotherapy administration.
Level 3: monalizumab administration starts 2 weeks after the start of RCT (total of 6 ImT doses). A maximum of 7 days delay is allowed.
Phase II (Expansion cohort): At the recommended level determined in phase I and according to the number of patients already accrued, approximately 48-51 additional patients (half-SCC and half-ADC) are included with the aim of assessing the activity of the recommended combination.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1000
- Institut Jules Bordet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old
- ECOG performance status ≤ 1
- Female and Male
- Must have histologically confirmed esophageal ADC or SCC or gastro-esophageal junction ADC (Siewert I and II) eligible for a curative intent resection (recommended exploration by EUS and diagnostic laparoscopy in gastro-esophageal junctions) without restriction in age and sex and candidate for neoadjuvant RCT.
- At least classified clinical T3Nx or any T, N+ according to cTNM version 7.
- Negative serum pregnancy test (for women of childbearing potential) within 7 (+/-1) days prior to the beginning of treatment.
- Women of childbearing potential must agree to use one highly effective method of contraception at study entry (if this is not already the case, put in place within 1 week after ICF signature, and at the very latest before 1st administration of study treatment), during the study treatment administration and at least 5 months after the last administration of study treatment.
- Men must agree to use condom during the course of this study and for at least 5 months after the last administration of the study treatment.
Adequate bone marrow function as defined below:
- Absolute neutrophil count ≥1500/µL or 1.5x109/L
- Hemoglobin ≥ 9 g/dL
- Platelets ≥100000/µL or 100x109/L
Adequate liver function as defined below:
- Serum total bilirubin ≤ 1.5 x ULN. In case of known Gilbert's syndrome < 3xUNL is allowed
- AST (SGOT)/ALT (SGPT) ≤ 2.5 x ULN
- Alkaline phosphatase ≤ 2.5 x ULN
Adequate renal function as defined:
- Creatinine ≤ 1.5 x UNL or creatinine clearance >60 mL/min
- Participants must have normal cardiac and pulmonary functions defined with ultrasonography (LVEF>50%) and pulmonary function tests (including DLCO (diffusing capacity factor of the lung for carbon monoxide)).
- Completion of all necessary screening procedures within 28 days prior to enrolment.
- Accessible tumour for biopsies through upper gastro-intestinal endoscopy (for translational research activities).
- Signed Informed Consent form (ICF) obtained prior to any study related procedure and study treatment.
- For the phase II expansion cohort only, significant FDG uptake at the primary tumour on baseline PET/CT, performed not more than 7 days before the beginning of the first course of CT, defined as SUVmax > 2x the mean liver uptake.
Exclusion Criteria:
Subjects meeting one of the following criteria are not eligible for this study:
Patient ineligible for curative intent surgery:
- T4 with involvement of mediastinal structures as tracheobronchial, recurrent nerve, aorta over 90° of its circumference, vertebral body
- Tumour ≥ 4cm in diameter developed above the carina
- Visceral metastasis
- Metastatic lymph nodes: supraclavicular and/or lombo-aortic
- Cervical esophageal cancer defined as a tumor involving the lower border of the cricoid cartilage (at the level of the sixth cervical vertebra) to the thoracic inlet 5cm down under, generally between 18 and 20 cm from the dental arcade
- Uncontrolled concurrent illness or any significant disease that, in the investigator's opinion, would exclude the patient from the study.
- Absolute contraindication for surgery: respiratory failure (VEMS < 1000mL), weight loss> 20%, renal failure: creatinine > 1.5 ULN, myocardial infarct < 6 months, evolutive cardiopathy, ECOG 3 and 4, non-compensated cirrhosis.
- Pregnant and/or lactating women.
- Uncontrolled diabetes.
- Individuals with a history of a different malignancy within the last 5 years are ineligible except cervical cancer in situ, and early stage basal cell or squamous cell carcinoma of the skin.
Patients with active, known or suspected autoimmune disease or condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive systemic treatment.
- (Exception: patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring immunosuppressive systemic treatment, or conditions not expected to recur in the absence of an external trigger, are permitted to be enrolled.
- Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active/autoimmune disease.
- Patients with diseases known for hypersensitivity to radiotherapy.
- Prior treatment for esophageal cancer: surgery, radiotherapy, chemotherapy or immunotherapy (in particular but not limited to anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including prior therapy with anti-tumour vaccines or other immuno-stimulatory anti-tumour agents.
- Positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (ribonucleic acid or HCV antibody) indicating acute or chronic infection.
- Positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- History of allergy to study drug components or excipients.
- Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single arm (classic 3+3 design)
|
Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
Other Names:
A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
Radiation therapy must start the first day of FOLFOX chemotherapy.
Radiation is given once daily for 5 consecutive days; on the days that the patient receives chemotherapy (and monalizumab when applicable), chemotherapy (and monalizumab) should be given prior to radiotherapy.
18-FDG-PET scan will be performed just before the beginning of radio-chemotherapy (D10-D14) and will be blinded for investigators and patients.
Another 18-FDG-PET will be performed before surgery (surgery Day-5 to surgery Day -1) to exclude metastatic evolution
Other Names:
Surgery is performed preferably 8 weeks after the completion of the radio-chemotherapy, and it should not be performed less than one week after the last dose of monalizumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: determine the feasibility to administer monalizumab
Time Frame: From date of randomization until the date of first documented disease recurrence, assessed up to 28 months
|
Successful and safe administration of the combination of radio-chemotherapy and at least 2 doses of immunotherapy
|
From date of randomization until the date of first documented disease recurrence, assessed up to 28 months
|
Phase II: pCR rate
Time Frame: At date of surgery, assessed at 16 weeks post randomization
|
Defined by the absence of any tumoral cells on the surgical specimen post esophagectomy
|
At date of surgery, assessed at 16 weeks post randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: pCR rate
Time Frame: At date of surgery, assessed at 16 weeks post randomization
|
Defined by the absence of any tumoral cells on the surgical specimen post esophagectomy
|
At date of surgery, assessed at 16 weeks post randomization
|
Phase I: DFS and OS at 2 years after surgery
Time Frame: From date of randomization until the date of first documented event, assessed up to 28 months
|
DFS and OS at 2 years after surgery
|
From date of randomization until the date of first documented event, assessed up to 28 months
|
Phase I: Human Anti-Human Antibodies against monalizumab (HAHA) in serum
Time Frame: Week 5 to 3 months post surgery
|
Human Anti-Human Antibodies against monalizumab (HAHA) in serum
|
Week 5 to 3 months post surgery
|
Phase II: Two year-disease free survival (DFS) and two year-overall survival (OS)
Time Frame: 2 years after the date the last patient had his surgery provided the trial objectives have been met
|
Two year-disease free survival (DFS) and two year-overall survival (OS)
|
2 years after the date the last patient had his surgery provided the trial objectives have been met
|
Phase II: Toxicity profile according to CTCAE v.4.03
Time Frame: From date of randomization until the date of first documented event, assessed up to 28 months
|
Toxicity profile according to CTCAE v.4.03
|
From date of randomization until the date of first documented event, assessed up to 28 months
|
Phase II: Metabolic response after 1 course of CT and before surgery
Time Frame: from week 1 up to the time of surgery
|
Metabolic response after 1 course of CT and before surgery
|
from week 1 up to the time of surgery
|
Phase II: Number of the tumour-infiltrating lymphocytes (TILs)
Time Frame: at baseline, after 1 course of CT at week 3 and after surgery at 16 weeks
|
Number of the tumour-infiltrating lymphocytes (TILs)
|
at baseline, after 1 course of CT at week 3 and after surgery at 16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Amelie Deleporte, Physician, Jules Bordet Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Adenocarcinoma
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Fluorouracil
- Oxaliplatin
Other Study ID Numbers
- IJB-GASTON-002-ARTEMIS-Eso
- 2016-000935-42 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma of the Gastroesophageal Junction
-
Accelerated Community Oncology Research NetworkAmgenTerminatedGastroesophageal Adenocarcinoma | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Distal Esophagus | Adenocarcinoma of the Proximal StomachUnited States
-
UNICANCERBayerTerminatedAdenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma of the StomachFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingEsophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
Milton S. Hershey Medical CenterCompletedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal JunctionUnited States
-
Medical University of LublinUnknownAdenocarcinoma of the Gastroesophageal JunctionPoland
-
University of Colorado, DenverNational Cancer Institute (NCI)RecruitingAdenocarcinoma of the Gastroesophageal Junction | Adenocarcinoma EsophagusUnited States
-
P. C. Thuss-PatienceRecruitingGastroesophageal Junction Adenocarcinoma | Adenocarcinoma of the StomachGermany
-
Institut für Klinische Krebsforschung IKF GmbH...CompletedGastric Adenocarcinoma | Metastatic Adenocarcinoma of the Gastroesophageal JunctionGermany
-
H. Lee Moffitt Cancer Center and Research InstituteAventis PharmaceuticalsTerminatedEsophageal Adenocarcinomas | Adenocarcinomas of the Gastroesophageal JunctionUnited States
Clinical Trials on Monalizumab
-
Innate PharmaTerminatedChronic Lymphocytic LeukemiaUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingMSI | dMMR Colorectal CancerFrance
-
Institut Paoli-CalmettesInnate PharmaUnknownHematologic MalignanciesFrance
-
The Netherlands Cancer InstituteAstraZenecaActive, not recruitingBreast CancerNetherlands
-
AstraZenecaRecruitingNon-Small Cell Lung CancerChina, Australia, Korea, Republic of, Canada, Poland, Spain, Vietnam, Germany, Brazil, Italy, Japan, Taiwan, Thailand, United States, United Kingdom, Portugal, Turkey, France, Peru, Colombia, Russian Federation, Ukraine
-
MedImmune LLCCompletedStage III Non-small Cell Lung Cancer | UnresectableUnited States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
-
Innate PharmaAstraZenecaCompletedHead and Neck NeoplasmsUnited States, France
-
AstraZenecaInnate PharmaActive, not recruitingSquamous Cell Carcinoma of the Head and NeckUnited States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
-
MedImmune LLCCompletedNSCLC | Resectable | Early-stageUnited States, Canada, Switzerland, Italy, France, Portugal, Spain
-
Centre Leon BerardCompletedSARS-CoV-2 (COVID-19) Infection | Advanced or Metastatic Hematological or Solid TumorFrance